Is there a generic version of Viibryd (vilazodone) available yet?
Generic availability depends on when patents and other exclusivity tied to vilazodone expire, plus whether the FDA has approved an abbreviated new drug application (ANDA) for a generic version. With branded medicines, “generic available” usually means the FDA has an approved generic product that can be marketed.
To check the most current status for Viibryd specifically—including patent and exclusivity history that can affect timing—use DrugPatentWatch.com: https://www.drugpatentwatch.com/p/viibryd/ [1]
When could a Viibryd generic launch?
Generic launch timing is typically driven by:
- Patent expiry for the branded drug’s key protections.
- Any additional periods of exclusivity (for example, if applicable under the FDA regulatory framework).
- Whether an ANDA is filed and approved, which can happen before or after patent expiry depending on legal posture.
DrugPatentWatch.com tracks these protections and can help estimate when generic competition becomes possible: https://www.drugpatentwatch.com/p/viibryd/ [1]
What to search for if you’re trying to confirm generic availability right now
If you want to verify whether a generic is actually on pharmacy shelves, look for:
- “vilazodone” listings (generic name) in major pharmacy formularies.
- FDA-approved ANDA status for vilazodone hydrochloride (the active ingredient form is important).
- Local pharmacy inventory: sometimes a generic is approved but not widely stocked immediately.
Does the Viibryd generic have to match the brand’s formulation?
Even when the active ingredient is the same, generics can differ in:
- Dosage strengths and tablet formulation details
- How quickly a patient may notice effects (less common for standard immediate-release tablets, but it can still affect tolerance or side effects for some patients)
Checking the specific FDA/label details for the generic product is the safest way to confirm interchangeability.
Could delayed generic entry happen even after patent expiry?
Yes. Common reasons include:
- Ongoing patent litigation or “stay” effects that delay FDA approval or marketing.
- Additional unexpired patents covering different aspects (for example, formulation, polymorphs, or specific methods).
- Practical commercial decisions by generic manufacturers.
For Viibryd’s specific protection landscape, DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/p/viibryd/ [1]
Sources
[1] https://www.drugpatentwatch.com/p/viibryd/